icon-folder.gif   Conference Reports for NATAP  
 
  The International Liver Congress™
EASL - European Association for the
Study of the Liver
June 22-26 2022
Back grey_arrow_rt.gif
 
 
 
Evaluation of the drug-drug interaction profile of vebicorvir,
a first-generation hepatitis B core inhibitor: findings from
Phase 1 and Phase 2a studies

 
 
  EASL: Deeper virologic suppression with the addition of vebicorvir, a first-generation hepatitis B core inhibitor, to entecavir correlates with reduced inflammation and fibrosis-4 index in treatment-na´ve patients with HBeAg positive chronic hepatitis B - (06/26/22)
 
EASL: ABI-4334, a novel inhibitor of hepatitis B virus core protein, promotes formation of empty capsids and prevents cccDNA formation by disruption of incoming capsids - (06/30/22)
 
EASL: Improving the pharmacokinetic profile of the hepatitis B virus core inhibitor ABI-H3733 following oral administration: results from new formulation activities - (06/26/22)
 
EASL 2022 June 22-26 London
 
Katie Zomorodi, Grace Wang, Steven J Knox, Julie Ma, Luisa M Stamm Assembly Biosciences, Inc., South San Francisco, CA, USA

0705221

0705222

0705223

0705224

0705225

0705226

0705227

0705228

0705229

07052210